ER

Elizabeth E. Sweeney, V. Craig Jordan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The estrogen receptor (ER) is the most valuable target in cancer therapeutics. The ER signal transduction pathway controls breast and endometrial tumor cell replication. Members of the group of medicines called Selective ER Modulators such as tamoxifen or raloxifene are antiestrogenic in the breast tumor but can build bone in postmenopausal women. Tamoxifen is used ubiquitously to treat all stages of breast cancer and to prevent breast cancer in high-risk women. Raloxifene is used to prevent breast cancer in high-risk postmenopausal women as to treat osteoporosis and prevent breast cancer at the same time.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages997-1006
Number of pages10
Volume2-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017

Keywords

  • Antihormone therapy
  • Assessment
  • Decision network
  • ERa
  • ERß
  • Estrogen receptor (ER)
  • Hormone receptor
  • Long-term antihormone therapy
  • Luminal A and B intrinsic subtypes
  • Nuclear receptor coregulator recruitment
  • Oophorectomy
  • Paradox
  • Prognosis
  • Raloxifene
  • Role in breast cancer
  • SERMs
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Tamoxifen
  • Therapeutics

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry, Genetics and Molecular Biology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'ER'. Together they form a unique fingerprint.

Cite this